VivoSeq
Other

Meropenem

0

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Meropenem is an early-stage landscape with 0 programs across 4 companies. The most active players are Melinta Therapeutics, Inc., Roche, Venatorx Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Melinta Therapeutics, Inc.

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalV

Venatorx Pharmaceuticals, Inc.

0 programs

PreclinicalS

Sumitovant Biopharma, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed12 · 75%
Unknown status3 · 19%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

16 trials

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers
Completed·Roche logoRoche·Phase 1·NCT02972255·46 enrolled
Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients
Completed·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT03645668·80 enrolled
Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
Completed·TTASK Applied Science·Phase 2·NCT04629378·22 enrolled
Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers
Completed·MMelinta Therapeutics, Inc.·Phase 1·NCT03564158·53 enrolled
Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
Completed·SSumitovant Biopharma, Inc.·Phase 1·NCT05226923·123 enrolled
Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects
Completed·AAntabio·Phase 1·NCT06527677·41 enrolled
FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects
Completed·AAntabio·Phase 1·NCT05905913·72 enrolled
Pharmacokinetics of Meropenem During High-dose CRRT
Completed·MMedical University of Lublin·N/A·NCT03507751·19 enrolled
Meropenem Dosage Strategy Based on PPK Model
Completed·—·Phase 4·NCT01944319·79 enrolled
Bolus Versus Continuous Infusion of Meropenem
Completed·UUniversità Vita-Salute San Raffaele·Phase 4·NCT03452839·607 enrolled
Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS
Completed·KKing Abdul Aziz Specialist Hospital·N/A·NCT04402359·200 enrolled
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
Completed·MMelinta Therapeutics, Inc.·Phase 3·NCT02166476·550 enrolled
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
Withdrawn·VVenatorx Pharmaceuticals, Inc.·Phase 3·NCT06168734
Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients
Unknown status·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·N/A·NCT04257838·200 enrolled
PK of Meropenem in Patients on Plasma Exchange
Unknown status·PPrince of Songkla University·N/A·NCT05042271·15 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)